Prediabetes

  1. How Prediabetes Is Defined
  2. Diagnostic Criteria
  3. Insulin Resistance vs. Beta-Cell Dysfunction
  4. Risk Factors
  5. Lifestyle Intervention — The Diabetes Prevention Program
  6. Metformin vs. Lifestyle Intervention
  7. Monitoring and Screening Intervals
  8. Nutrition and Exercise Strategies
  9. Key Research Papers
  10. Connections
🩸 Interactive Visualization Blood Sugar & Insulin — eat a meal and watch glucose move Watch insulin escort glucose into cells and the liver bank glycogen, then switch on insulin resistance and see the curve change. Launch → ⛽ Interactive Visualization Fat Burning & Ketosis — what actually happens Follow a fatty acid out of a fat cell to the mitochondrial gate and find it padlocked by insulin. Drop the carbs, open CPT1, and watch the liver start making ketones. Launch → 💉 Interactive Visualization glucagon-like peptide-1 (GLP-1) & Incretins — fire the gut hormone behind the new weight-loss drugs Eat a meal and watch your gut fire glucagon-like peptide-1 at the pancreas, brain and stomach at once — then see how semaglutide-type drugs resist the enzyme that destroys it in two minutes. Launch → 🍯 Interactive Visualization Glycation & hemoglobin A1c (HbA1c) — sugar-coat a red cell and watch the number lag Coat red blood cells in glucose for 120 days and watch hemoglobin A1c emerge as their average — then normalize the sugar today and see why the number takes months to follow. Launch →

How Prediabetes Is Defined

Blood glucose is above normal but below the threshold for diabetes. American Diabetes Association (ADA) 2024 criteria: fasting glucose 100–125 mg/dL (impaired fasting glucose), or hemoglobin A1c 5.7–6.4%, or 2-hour OGTT glucose 140–199 mg/dL. An estimated 96 million U.S. adults have prediabetes; 80% are undiagnosed (U.S. Centers for Disease Control and Prevention (CDC) 2022). Without intervention, approximately 37% progress to type 2 diabetes within 4 years.

Back to Table of Contents

Diagnostic Criteria

Three equivalent screening tests: (1) Fasting plasma glucose (FPG) 100–125 mg/dL — taken after fasting ≥8 hours. (2) hemoglobin A1c 5.7–6.4% — reflects 2–3 month average; affected by hemoglobinopathies, iron deficiency, kidney disease. (3) Oral glucose tolerance test (OGTT) 2-hour value 140–199 mg/dL after 75 g glucose load — most sensitive, catches isolated postprandial dysglycemia. Any single abnormal result on a high-risk individual warrants a repeat test to confirm.

Back to Table of Contents

Insulin Resistance vs. Beta-Cell Dysfunction

Prediabetes arises from two overlapping defects. Insulin resistance: skeletal muscle, liver, and adipose tissue respond less effectively to insulin — driven by visceral fat, physical inactivity, inflammation, and lipotoxicity. Beta-cell dysfunction: pancreatic beta cells fail to compensate with adequate insulin secretion — early impairment of first-phase insulin release is characteristic. IFG (elevated fasting glucose) reflects primarily hepatic insulin resistance and impaired fasting insulin suppression. IGT (elevated post-OGTT glucose) reflects more peripheral (muscle) insulin resistance and beta-cell exhaustion. Both defects coexist in most people with prediabetes.

Back to Table of Contents

Risk Factors

Age ≥45, body mass index (BMI) ≥25 kg/m² (≥23 in Asian Americans), family history of type 2 diabetes (first-degree), gestational diabetes history, polycystic ovary syndrome (PCOS), physical inactivity, hypertension (≥130/80 mmHg or on treatment for high blood pressure), dyslipidemia (high-density lipoprotein (HDL) <35 mg/dL or triglycerides >250 mg/dL), history of cardiovascular disease, acanthosis nigricans, sleep apnea, antipsychotic medication use, and certain ethnic groups (Hispanic/Latino, Black, Asian American, Native American — higher incidence at lower body mass index).

Back to Table of Contents

Lifestyle Intervention — The Diabetes Prevention Program

The landmark DPP RCT (NEJM 2002, n=3,234) showed intensive lifestyle intervention reduced type 2 diabetes incidence by 58% over 2.8 years versus placebo. Goals: ≥7% body weight loss and ≥150 min/week of moderate activity. Metformin arm reduced risk by 31%. The DPP Outcomes Study (DPPOS) kept following participants: over the 10 years since randomisation, diabetes incidence was 34% lower in the lifestyle group and 18% lower in the metformin group than with placebo (Lancet 2009); after a mean of 15 years it was 27% lower with lifestyle and 18% lower with metformin (Lancet Diabetes Endocrinol 2015). U.S. Centers for Disease Control and Prevention-recognized National DPP is now covered by Medicare for beneficiaries with prediabetes.

Back to Table of Contents

Metformin vs. Lifestyle Intervention

The American Diabetes Association's 2024 Standards of Care state that metformin “should be considered” alongside lifestyle change in adults at high risk of type 2 diabetes, especially those aged 25–59 years with body mass index ≥35 kg/m², fasting plasma glucose ≥110 mg/dL, and hemoglobin A1c ≥6.0%, and in people with prior gestational diabetes. The ADA names no dose; the DPP trial used metformin 850 mg twice daily. The same Standards note that long-term metformin use may be associated with vitamin B12 deficiency, and suggest periodic vitamin B12 measurement, especially in people with anemia or nerve damage (peripheral neuropathy). Head-to-head in DPP: lifestyle outperformed metformin overall, but metformin was more effective in younger patients and those with higher body mass index. Metformin is not U.S. Food and Drug Administration-approved for prediabetes prevention (used off-label); it costs ~$4/month generic. Lifestyle is first-line because it also reduces cardiovascular risk factors beyond glucose. Both interventions are synergistic; neither cures the underlying defect.

Back to Table of Contents

Monitoring and Screening Intervals

The ADA's 2024 Standards state that for people without risk factors, screening begins at age 35. The same Standards call for yearly testing in people with prediabetes; the 3-year interval applies to people whose results are normal. Follow-up commonly tracks: fasting glucose, hemoglobin A1c, lipid panel, blood pressure, kidney function (estimated glomerular filtration rate (eGFR), urine albumin-to-creatinine ratio). Regression to normoglycemia occurs in about 40% of people with prediabetes over 4 years and is associated with weight loss, younger age, and lower baseline glucose.

Back to Table of Contents

Nutrition and Exercise Strategies

Dietary approaches: Mediterranean diet, DASH, and low-carbohydrate diets all show benefit in reducing hemoglobin A1c and fasting glucose. Key principles: reduce refined carbohydrates and sugar-sweetened beverages, increase dietary fiber (≥25 g/day), prefer whole grains, legumes, and non-starchy vegetables. Exercise: aerobic exercise (brisk walking, cycling) improves peripheral insulin sensitivity; resistance training independently lowers hemoglobin A1c; combination is superior. Structured programs achieving ≥150 min/week of moderate activity are equivalent to pharmaceutical interventions for many patients.

Back to Table of Contents

Key Research Papers

  1. Knowler WC et al. (DPP), 2002 — Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346(6):393-403. — PubMed PMID: 11832527
  2. Diabetes Prevention Program Research Group, 2009 — 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet. 2009;374(9702):1677-1686. — PubMed PMID: 19878986
  3. Diabetes Prevention Program Research Group, 2015 — Long-term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15-year follow-up: the Diabetes Prevention Program Outcomes Study. Lancet Diabetes Endocrinol. 2015;3(11):866-875. — PubMed PMID: 26377054
  4. American Diabetes Association Professional Practice Committee, 2024 — 3. Prevention or Delay of Diabetes and Associated Comorbidities: Standards of Care in Diabetes-2024. Diabetes Care. 2024;47(Suppl 1):S43-S51. — PubMed PMID: 38078581
  5. American Diabetes Association Professional Practice Committee, 2024 — 2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes-2024. Diabetes Care. 2024;47(Suppl 1):S20-S42. — PubMed PMID: 38078589
  6. Tabak AG et al., 2012 — Prediabetes: a high-risk state for diabetes development. Lancet. 2012;379(9833):2279-2290. — PubMed PMID: 22683128
  7. Perreault L et al. — Regression from prediabetes to normal glucose regulation. Lancet. 2012;379(9833):2243-2251. — PubMed PMID: 22683134
  8. Gerstein HC, Santaguida P, Raina P, et al., 2007 — Annual incidence and relative risk of diabetes in people with various categories of dysglycemia: a systematic overview and meta-analysis of prospective studies. Diabetes Res Clin Pract. 2007;78(3):305-312. — PubMed PMID: 17601626
  9. Tuomilehto J et al. (Finnish DPS), 2001 — Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001;344(18):1343-1350. — PubMed PMID: 11333990
  10. Haw JS, Galaviz KI, Straus AN, et al., 2017 — Long-term sustainability of diabetes prevention approaches: a systematic review and meta-analysis of randomized clinical trials. JAMA Intern Med. 2017;177(12):1808-1817. — PubMed PMID: 29114778
  11. Lily M, Godwin M, 2009 — Treating prediabetes with metformin: systematic review and meta-analysis. Can Fam Physician. 2009;55(4):363-369. — PubMed PMID: 19366942
  12. Salas-Salvado J et al. (PREDIMED), 2011 — Reduction in the incidence of type 2 diabetes with the Mediterranean diet. Diabetes Care. 2011;34(1):14-19. — PubMed PMID: 20929998
  13. Colberg SR et al., 2010 — Exercise and type 2 diabetes. Diabetes Care. 2010;33(12):e147-e167. — PubMed PMID: 21115758
  14. Blonde L, Umpierrez GE, Reddy SS, et al., 2022 — American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan—2022 Update. Endocr Pract. 2022;28(10):923-1049. — PubMed PMID: 35963508

PubMed Topic Searches

  1. PubMed: Prediabetes lifestyle intervention
  2. PubMed: Prediabetes metformin prevention
  3. PubMed: HbA1c prediabetes diagnosis
  4. PubMed: OGTT impaired glucose tolerance
  5. PubMed: Diabetes prevention program outcomes
  6. PubMed: Insulin resistance prediabetes
  7. PubMed: Prediabetes regression normoglycemia
  8. PubMed: Mediterranean diet prediabetes

Back to Table of Contents

Connections